Korean Journal of Pediatrics 2010;53(3):358-363.
Published online March 15, 2010.
Effect of SynagisⓇ (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants
Soo Kyoung Park1, Yu Jin Jung2, Hye Soo Yoo1, So Yoon Ahn1, Hyun Joo Seo1, Seo Heui Choi1, Myo Jing Kim3, Ga Won Jeon4, Soo Hyun Koo5, Kyung-Hoon Lee6, Yun Sil Chang1, Won Soon Park1
1Department of Pediatrics, Samsung Medical Center, Seoul, Korea
2Department of Pediatrics, Kosin University College of Medicine, Busan, Korea
3Department of Pediatrics, Dong-A University College of Medicine, Busan, Korea
4Department of Pediatrics, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
5Department of Pediatrics, Masan Samsung Hospital, Masan, Korea
6Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Korea
극소 저체중 출생아에서 SynagisⓇ (palivizumab) 접종이 respiratory syncytial virus 감염으로 인한 재입원에 미치는 영향
박수경1, 정유진2, 유혜수1, 안소윤1, 서현주1, 최서희1, 김묘징3, 전가원4, 구수현5, 이경훈6, 장윤실1, 박원순1
1성균관대학교 의과대학 삼성서울병원 소아청소년과
2고신대학교 의과대학 소아과학교실
3동아대학교 의과대학 소아과학교실
4인제대학교 의과대학 부산백병원 소아청소년과
5마산산삼성병원 소아청소년과
6마산산삼성병원 분자세포생물학교실
Won Soon Park, Email: wonspark@skku.edu
Received: 16 October 2009   • Revised: 16 December 2009   • Accepted: 14 February 2010
: The aim of this study was to determine the efficacy of SynagisⓇ (palivizumab) in reducing the respiratory syncytial virus (RSV) readmission rate in very low birth weight infants (VLBWI ) and the subgroup that showed the most effective vaccination.
: We enrolled 350 VLBWI who had been discharged alive from the neonatal intensive care unit of Samsung Medical Center from January 2005 to December 2007 and were followed up for at least one year. A retrospective study based on medical records was performed for a period of one year after discharge. RSV readmission rate was investigated according to BPD (bronchopulmonary dysplasia, requiring oxygen at postnatal day 28) and SynagisⓇ prophylaxis. We categorized the subgroups by the severity of BPD gestational age, and birth weight and compared the RSV readmission rates between subgroups.
: Eleven VLBWI were readmitted. SynagisⓇ prophylaxis resulted in a 86% reduction in the rate of readmission due to RSV infection (prophylaxis group, 0.7% and no prophylaxis group, 5.0%; P=0.02). Readmission rate in BPD patients was also reduced in the prophylaxis group (0.7% in the prophylaxis group vs. 5.2% in the no prophylaxis group, P= 0.03). The readmission rate in patients without BPD was reduced in the prophylaxis group (0% in the prophylaxis group vs. 4.9% in the no prophylaxis group, P=1.00), but this was not statistically significant.
: SynagisⓇ prophylaxis was effective at reducing RSV readmission in VLBWI. Its efficacy was verified irrespective of BPD, gestational age, or birth weight.
Key Words: RSV, SynagisⓇ, Very low birth weight, Readmission

METRICS Graph View
  • 2,734 View
  • 42 Download

Close layer
prev next